Research location
Itabashi-ku, Tokyo
Japan
Advertisement
Research activity in Itabashi-ku, Tokyo
JapanCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Itabashi-ku, Tokyo
8 linked trials · page 1 of 1A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.NCT02607306 · 2015-11-18 · 2 site observations
COMPLETED
Add-on to Micamlo BP TrialNCT01975246 · 2013-11-01 · 1 site observation
COMPLETED
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)NCT01431274 · 2011-09-01 · 1 site observation
COMPLETED
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent AsthmaNCT01340209 · 2011-04-01 · 1 site observation
COMPLETED
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma IINCT01172821 · 2010-08-01 · 1 site observation
COMPLETED
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPDNCT00824382 · 2009-01-01 · 1 site observation
COMPLETED
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)NCT00776984 · 2008-10-01 · 1 site observation
COMPLETED
Filtered Trial for Amlodipine Non-responderNCT00558064 · 2007-10-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.